Aliases:This biomarker is also known as:
- prostate cancer antigen 3 (non-protein coding),
- non-protein coding RNA 19,
- prostate cancer antigen 3,
The prostate cancer antigen 3 (PCA3/DD3) gene is a highly specific biomarker upregulated in prostate cancer. Because there is no extensive open reading frame, the gene is thought to express a noncoding RNA.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
The prostate cancer antigen 3 (PCA3/DD3) gene is a highly specific biomarker upregulated in prostate cancer. The PCA3 gene (prostate cancer antigen 3) is a non-coding gene that is over-expressed in prostate cancer. PCA3 in conjunction with other clinical tools has been shown to be as effective as the PSA (prostate specific antigen) assay in predicting the presence of prostate cancer. The FDA recently approved the first molecular test that uses PCA3 to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
The FDA has approved an assay for prostate cancer that uses the ratio of PCA3 RNA to PSA RNA in urine. The assay is used to help physicians determine the need for repeat prostate biopsies in men 50 years of age or older who have had a previous negative biopsy. When used in conjunction with other clinical information, the use of this test can reduce the need for unnecessary prostate biopsies.
- A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
- Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
- Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
- Correlation of Urine TMPRSS2:ERG and PCA3 to ERG+ and Total Prostate Cancer Burden.
- Rational approach to implementation of prostate cancer antigen 3 into clinical care.
- Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.